| Issue Date | Title | Author(s) |
| 2023-12-06 | Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer. | Buteau, JP; Moon, D; Fahey, MT; Roberts, MJ; Thompson, J; Murphy, DG; Papa, N; Mitchell, C; De Abreu Lourenco, R; Dhillon, HM; Kasivisvanathan, V; Francis, RJ; Stricker, P; Agrawal, S; O'Brien, J; McVey, A; Sharma, G; Levy, S; Ayati, N; Nguyen, A; Lee, S-F; Pattison, DA; Sivaratnam, D; Frydenberg, M; Du, Y; Titus, J; Lee, S-T; Ischia, J; Jack, G; Hofman, MS; Emmett, L |
| 2021-01-27 | Correction to: Navigate: a study protocol for a randomised controlled trial of an online treatment decision aid for men with low-risk prostate cancer and their partners | Schofield, P; Gough, K; Hyatt, A; White, A; Frydenberg, M; Chambers, S; Gordon, LG; Gardiner, R; Murphy, DG; Cavedon, L; Richards, N; Murphy, B; Quinn, S; Juraskova, I |
| - | Co‐designing an online treatment decision aid for men with low‐risk prostate cancer: Navigate | Schofield, P; Hyatt, A; White, A; White, F; Frydenberg, M; Chambers, S; Gardiner, R; Murphy, DG; Cavedon, L; Millar, J; Richards, N; Murphy, B; Juraskova, I |
| 2020-12-16 | Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial. | de Feria Cardet, RE; Hofman, MS; Segard, T; Yim, J; Williams, S; Francis, RJ; Frydenberg, M; Lawrentschuk, N; Murphy, DG; De Abreu Lourenco, R |
| 2021-01-11 | Navigate: a study protocol for a randomised controlled trial of an online treatment decision aid for men with low-risk prostate cancer and their partners | Schofield, P; Gough, K; Hyatt, A; White, A; Frydenberg, M; Chambers, S; Gordon, LG; Gardiner, R; Murphy, DG; Cavedon, L; Richards, N; Murphy, B; Quinn, S; Juraskova, I |
| 2023-02-20 | PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer. | Buteau, JP; Moon, D; Fahey, MT; Roberts, M; Thompson, J; Murphy, DG; Papa, N; Mitchell, C; Kasivisvanathan, V; Stricker, P; O'Brien, J; Counter, W; Sharma, G; Agrawal, S; Ho, B; Yeung, T; De Abreu Lourenço, R |
| 2018-11-01 | A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol | Hofman, MS; Murphy, DG; Williams, SG; Nzenza, T; Herschtal, A; De Abreu Lourenco, R; Bailey, DL; Budd, R; Hicks, RJ; Francis, RJ; Lawrentschuk, N |
